Following breast cancer diagnosis, non-breast cancer causes of death represented a significant number of deaths in this population, providing crucial understanding on how survivors should be counseled on future health risks.
The criterion-based valuation framework was created with the intention of being revised as public feedback is ascertained and the landscape of cancer care evolves.
Opportunities to further eradicate opioid use as a complication of cancer care should continue to be explored regardless of the data presented according to researchers.
This research could potentially pave the way for possible immunotherapy approaches for common forms of non-Hodgkin lymphoma.
The breakthrough therapy designation was filed for the use of leronlimab as an adjuvant therapy for patients with metastatic triple-negative breast cancer.
The priority review was based on results from the phase III PAOLA-1 trial comparing the addition of olaparib to bevacizumab vs the standard-of-care alone.
This study indicated that caregivers saw improved quality of life, reduced caregiving burden, lower anxiety and depression symptoms, and improved self-efficacy and coping skills having received psychosocial intervention.
Data from the ongoing phase I/II ARROW clinical trial will be used to support a new drug application submission for pralsetinib to the FDA for the treatment of patients with RET fusion-positive non-small cell lung cancer.
Authors indicated that reductions in smoking and treatment breakthroughs have led to this steady decline.
This study indicated the necessity for healthcare providers to initiate discussions on the experience of hearing loss for cancer survivors, as well as care options and interventions.